Superinfections in patients treated with Teicoplanin as anti-SARS-CoV-2 agent

Eur J Clin Invest. 2021 Jan;51(1):e13418. doi: 10.1111/eci.13418. Epub 2020 Oct 14.

Authors

Giancarlo Ceccarelli^{1

2}, Francesco Alessandri^{2

3}, Alessandra Oliva^{1

2}, Serena Dell'Isola⁴, Monica Rocco⁵, Franco Ruberto^{2

3}, Francesco Pugliese^{2

3}, Gabriella d'Ettorre^{1

2}, Mario Venditti^{1

2}

Affiliations

¹ Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
² Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy.
³ Department of Anaesthesiology and Intensive Care, Sapienza University of Rome, Rome, Italy.
⁴ Belcolle Hospital, Viterbo, Italy.
⁵ Intensive Care Unit, S. Andrea Hospital, Sapienza University of Rome, Rome, Italy.

No abstract available

Publication types

Letter

MeSH terms

Acinetobacter Infections / epidemiology
Aged
Anti-Bacterial Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use
Azithromycin / therapeutic use
Bacteremia / epidemiology*
COVID-19 Drug Treatment*
Candidemia / epidemiology
Enzyme Inhibitors / therapeutic use
Female
Gram-Negative Bacterial Infections / epidemiology*
Humans
Hydroxychloroquine / therapeutic use
Italy / epidemiology
Klebsiella Infections / epidemiology
Male
Methicillin-Resistant Staphylococcus aureus
Middle Aged
Pneumonia, Ventilator-Associated / epidemiology*
Protective Factors
Pseudomonas Infections / epidemiology
Respiration, Artificial
SARS-CoV-2
Staphylococcal Infections / epidemiology*
Superinfection / epidemiology*
Teicoplanin / therapeutic use*

Substances

Anti-Bacterial Agents
Antibodies, Monoclonal, Humanized
Enzyme Inhibitors
Hydroxychloroquine
Teicoplanin
Azithromycin
tocilizumab